Chemours Company (CC) concluded trading on Thursday at a closing price of $11.68, with 3.71 million shares of worth about $43.29 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -34.09% during that period and on June 26, 2025 the price saw a gain of about 2.46%. Currently the company’s common shares owned by public are about 149.57M shares, out of which, 148.55M shares are available for trading.
Stock saw a price change of 6.18% in past 5 days and over the past one month there was a price change of 9.98%. Year-to-date (YTD), CC shares are showing a performance of -49.83% which decreased to -30.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.13 but also hit the highest price of $25.54 during that period. The average intraday trading volume for Chemours Company shares is 3.64 million. The stock is currently trading 7.69% above its 20-day simple moving average (SMA20), while that difference is up 3.95% for SMA50 and it goes to -27.34% lower than SMA200.
Chemours Company (NYSE: CC) currently have 149.57M outstanding shares and institutions hold larger chunk of about 97.00% of that.
The stock has a current market capitalization of $1.75B and its 3Y-monthly beta is at 1.63. PE ratio of stock for trailing 12 months is 56.75, while it has posted earnings per share of $0.21 in the same period. Its PEG reads 1.72 and has Quick Ratio of 0.83 while making debt-to-equity ratio of 7.57. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CC, volatility over the week remained 4.62% while standing at 5.52% over the month.
Stock’s fiscal year EPS is expected to rise by 32.80% while it is estimated to increase by 52.68% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on March 27, 2025 offering an Outperform rating for the stock and assigned a target price of $19 to it. Coverage by Truist stated Chemours Company (CC) stock as a Buy in their note to investors on January 28, 2025, suggesting a price target of $27 for the stock. On July 09, 2024, UBS Upgrade their recommendations, while on June 07, 2024, Mizuho Initiated their ratings for the stock with a price target of $25. Stock get an Outperform rating from BMO Capital Markets on April 09, 2024.
